期刊
SEMINARS IN LIVER DISEASE
卷 35, 期 3, 页码 338-348出版社
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0035-1562951
关键词
nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; vitamin E; thiazolidinedione; obeticholic acid
资金
- NIDDK NIH HHS [P30 DK097512] Funding Source: Medline
Lifestyle modifications and optimization of the management of cardiometabolic comorbidities are currently the mainstay of treatment for patients with nonalcoholic fatty liver disease. Pharmacotherapy to halt or reverse hepatic histological injury and prevent the development of end-stage liver disease is specifically offered to patients with nonalcoholic steatohepatitis (NASH) and those with advanced fibrosis. In this review, the authors discuss the state of the art of various pharmacological agents for NASH. The efficacy of vitamin E and pioglitazone is reasonably well established in a selected group of patients with NASH. Current data do not offer convincing evidence for efficacy of pentoxifylline, long-chain polyunsaturated fatty acids, angiotensin receptor blockers, metformin, or ursodeoxycholic acid. They also discuss the state of several emerging agents for treating NASH including the farsenoid X receptor ligand, obeticholic acid.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据